Strategic partnerships Leverage Marinomed's Marinosolv® platform and ongoing collaboration activity (Phargentis SA, Gaia Healthcare partnership, formulation services) to offer joint development programs, licensing discussions, or contract R&D services targeting respiratory and inflammatory indications.

Respiratory focus Target customers in inhalation and respiratory treatment spaces who could benefit from improved solubility and bioavailability of poorly soluble compounds via Marinosolv®, especially for immune-related and inflammatory respiratory disorders.

Ophthalmic expansion Explore opportunities in ophthalmology where Solv4U and Marinosolv-derived formulations could enable novel therapies, aligning with Marinomed’s existing platform to pitch early-stage development or co-development deals.

Financial signals With revenue under one million and recent strategic financings, present capital-efficient partnerships, milestone-driven agreements, and convertible-financing aligned collaborations to support pipeline acceleration without large upfront costs.

Investor & visibility Engage in investor-focused BD activities by offering transparent, partnership-driven stories around Marinosolv® technology, potential scale of manufacturing partnerships, and pipeline milestones to attract strategic investors and co-development partners.